自我免疫疾病市場：2014年之前的預測 是由出版商Cutting Edge Information在2009年06月所出版的。
這份英文市場調查報告書包含293 Pages 價格從美金6995起跳。
自我免疫疾病市場仍是處於暢銷藥品主導的時代，14種品牌藥每年至少創造30億美元的銷售成績。
本報告書內容包括：以風濕性關節炎、潰瘍性大腸炎、克隆病、多發性硬化症、乾癬、狼瘡等主要疾病為對象的40種藥物介紹及9家主要製造商介紹。內容綱要摘記如下：
封面圖片：
自我免疫疾病市場的主要動向
- 生物製劑會一直領導該市場嗎？
- 自我免疫疾病：製藥企業是否被過小評價？
自我免疫疾病概要
- 風濕性關節炎
- 乾癬
- 乾癬性關節炎
- 潰瘍性大腸炎
- 克隆病
- 多發性硬化症
- 全身性紅斑性狼瘡
- 狼瘡腎炎
針對自我免疫疾病的生物製劑治療
- TNF阻礙劑
- 干擾素Beta
- B細胞阻礙劑
- 介白素阻礙劑
- 其他
針對自我免疫疾病的小分子治療
- 免疫調整劑
- NSAID
- 5-ASA
- 腎上皮質類固醇
- 代謝拮抗物質
- JAK阻礙劑
- 其他
自我免疫疾病治療藥製造商介紹
- Abbott
- Roche
- Centocor
- biogen Idec
- Amgen
- Pfizer
- Teva
- Schering-Plough
- Merck KGaA
圖表
Abstract
Drive blockbuster revenue with autoimmune breakthroughs
The autoimmune market is proving that the era of the blockbuster is not dead.
Of 14 brands already at or expected to reach blockbuster status, half generate
at least $3 billion annually. Nine mid-level products will generate $400
million, at minimum, by 2014. For autoimmune drugs, reaching blockbuster-level
success is an expectation as much as a goal.
Whether you' re exploring your options or need to increase your presence in the
market, autoimmune compounds provide lucrative opportunities -- don' t miss out!
From sales projections to clinical trial data to analysts' insights,
Autoimmune Market Forecast to 2014 tells you everything you need to know.
Unlike other market forecast reports out there, ours covers all of the major
indications - rheumatoid arthritis, ulcerative colitis, Crohn' s disease,
multiple sclerosis, psoriasis and lupus - profiling 40+ drugs and nine leading
autoimmune product manufacturers.
Delve into the data to:
- Learn how brands and drug classes have fared: where they' ve succeeded -
and failed
- Show solid, objective evidence for your decision-making
- Keep track of the competition
- Get the latest on clinical trials
- Uncover potential business development opportunities
Research Methodology
Cutting Edge Information analysts gathered data from primary and secondary
sources to develop this report. Sources include interviews with key
executives; company publications, news releases and government filings;
industry analyst publications and forecasts; US and European government
documents clinical development and sales databases,including BioPharm lnsight;
patientadvocacy groups; industry periodicals; and othersources.
Scope of Research
All meta-analyses of companies, drug classes and indications are built upon
and limited to the drugs profiled within the report.
Table of Contents
Chapter 1: Autoimmune Indication Snapshots
This section provides historical context, possible causes, epidemiological
data, treatment information and new developments for each of the following
major autoimmune indications:
- Rheumatoid arthritis
- Psoriasis and psoriatic arthritis
- Ulcerative colitis
- Crohn' s disease
- Systemic lupus erythematosus and lupus nephritis
- Multiple sclerosis
Chapters 2 and 3: Brand profiles for Biologic and Small Molecule Therapies
Organized by class, brand profiles include the following points:
- Drug' s current and projected competitive strength
- Sales projection charts through 2014
- Materiality charts
- Clinical trial information
- Patent/market exclusivity tables
Classes covered in the report:
- TNF inhibitors
- B-cell inhibitors
- Interferon betas
- Interleukin inhibitors
- Immunomodulators
- NSAIDs
- 5-ASAs
- Antimetabolites
- Corticosteroids
- JAK inhibitors
Chapter 4: Autoimmune Drug Manufacturer Profiles
This chapter provides analysis of nine top autoimmune drug makers' portfolios.
Company profiles include:
- Ranking within market
- Strengths analysis
- Growth areas analysis
- Key products breakdown
